Alnera Aluminium
301613
Tibet Duo Rui Pharmaceutical
301075
ChengDu Sheng Nuo Biotec
688117
4
THEC
833509
5
Nanjing Railway New Technology
301016
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.24%738.68M | 19.94%199.89M | 17.35%185.62M | 14.50%177.5M | 16.96%175.67M | 17.13%630.04M | 15.89%166.65M | 19.06%158.18M | 17.84%155.02M | 15.82%150.19M |
Operating revenue | 17.24%738.68M | 19.94%199.89M | 17.35%185.62M | 14.50%177.5M | 16.96%175.67M | 17.13%630.04M | 15.89%166.65M | 19.06%158.18M | 17.84%155.02M | 15.82%150.19M |
Cost of revenue | 11.56%172.06M | 20.73%45.69M | 13.86%43.67M | 4.22%41.17M | 7.80%41.52M | 18.74%154.22M | 10.16%37.85M | 18.31%38.36M | 22.54%39.5M | 24.76%38.52M |
Gross profit | 19.08%566.63M | 19.71%154.2M | 18.47%141.95M | 18.02%136.33M | 20.12%134.14M | 16.62%475.82M | 17.69%128.81M | 19.31%119.82M | 16.32%115.52M | 13.03%111.67M |
Operating expense | 12.77%643.16M | 21.14%167.52M | 20.97%163.73M | 15.39%159.48M | -3.84%152.43M | 14.81%570.34M | 12.68%138.28M | 3.67%135.35M | 8.39%138.21M | 36.67%158.51M |
Selling and administrative expenses | 13.25%450.22M | 22.13%116.91M | 23.19%115.31M | 16.29%111.07M | -5.14%106.93M | 15.22%397.55M | 13.08%95.73M | 1.78%93.6M | 8.13%95.51M | 40.74%112.72M |
-Selling and marketing expense | 20.98%347.24M | 25.45%90.16M | 23.67%89.76M | 17.83%84.7M | 16.86%82.63M | 17.03%287.04M | 19.02%71.87M | 12.42%72.58M | 11.93%71.88M | 26.04%70.71M |
-General and administrative expense | -6.82%102.98M | 12.14%26.76M | 21.54%25.55M | 11.63%26.38M | -42.16%24.3M | 10.76%110.52M | -1.70%23.86M | -23.29%21.02M | -2.00%23.63M | 75.09%42.01M |
Research and development costs | 11.66%192.94M | 18.92%50.61M | 16.00%48.43M | 13.38%48.41M | -0.65%45.5M | 13.89%172.79M | 11.78%42.56M | 8.20%41.75M | 8.98%42.7M | 27.61%45.79M |
Operating profit | 19.03%-76.53M | -40.61%-13.32M | -40.30%-21.78M | -2.03%-23.15M | 60.97%-18.28M | -6.49%-94.53M | 28.65%-9.47M | 48.45%-15.53M | 19.52%-22.69M | -172.70%-46.84M |
Net non-operating interest income expense | 195.58%26.53M | -14.37%6.11M | 115.19%6.1M | 133.83%7.1M | 225.95%7.22M | -2,288.73%-27.76M | 577.49%7.13M | -57,247.14%-40.14M | 434.73%3.04M | 279.00%2.22M |
Non-operating interest income | 52.21%39.4M | -9.97%9.31M | 27.47%9.3M | 127.92%10.34M | 181.28%10.46M | 430.37%25.88M | 304.54%10.34M | 406.53%7.29M | 649.59%4.54M | 1,227.50%3.72M |
Non-operating interest expense | -76.02%12.87M | -0.16%3.2M | -93.26%3.2M | 115.94%3.24M | 115.32%3.23M | 787.77%53.64M | 113.18%3.2M | 3,041.52%47.44M | -0.86%1.5M | -1.12%1.5M |
Other net income (expense) | 131.04%563K | 339.56%872K | -392.96%-350K | 89.75%-45K | 109.15%86K | -295.90%-1.81M | 32.72%-364K | -107.37%-71K | -165.72%-439K | -469.70%-940K |
Other non- operating income (expenses) | 131.04%563K | 339.56%872K | -392.96%-350K | 89.75%-45K | 109.15%86K | -295.90%-1.81M | 32.72%-364K | -107.37%-71K | -165.72%-439K | -469.70%-940K |
Income before tax | 60.16%-49.44M | -134.52%-6.34M | 71.24%-16.03M | 19.89%-16.1M | 75.92%-10.97M | -39.44%-124.1M | 78.82%-2.7M | -90.73%-55.74M | 29.33%-20.09M | -145.24%-45.57M |
Income tax | 63.44%5.6M | 65.84%2.48M | 80.94%959K | 77.41%1.45M | 21.88%713K | 76.01%3.43M | 31.31%1.49M | 13.49%530K | 90.47%819K | 772.41%585K |
Net income | 56.84%-55.04M | -110.08%-8.82M | 69.80%-16.99M | 16.08%-17.55M | 74.68%-11.69M | -40.22%-127.53M | 69.82%-4.2M | -89.52%-56.27M | 27.55%-20.91M | -149.55%-46.15M |
Net income continuous Operations | 56.84%-55.04M | -110.08%-8.82M | 69.80%-16.99M | 16.08%-17.55M | 74.68%-11.69M | -40.22%-127.53M | 69.82%-4.2M | -89.52%-56.27M | 27.55%-20.91M | -149.55%-46.15M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 56.84%-55.04M | -110.08%-8.82M | 69.80%-16.99M | 16.08%-17.55M | 74.68%-11.69M | -40.22%-127.53M | 69.82%-4.2M | -89.52%-56.27M | 27.55%-20.91M | -149.55%-46.15M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 56.84%-55.04M | -110.08%-8.82M | 69.80%-16.99M | 16.08%-17.55M | 74.68%-11.69M | -40.22%-127.53M | 69.82%-4.2M | -89.52%-56.27M | 27.55%-20.91M | -149.55%-46.15M |
Basic earnings per share | 58.05%-0.99 | -100.00%-0.16 | 70.19%-0.31 | 17.95%-0.32 | 75.58%-0.21 | -37.21%-2.36 | 69.23%-0.08 | -85.71%-1.04 | 29.09%-0.39 | -145.71%-0.86 |
Diluted earnings per share | 58.05%-0.99 | -100.00%-0.16 | 70.19%-0.31 | 17.95%-0.32 | 75.58%-0.21 | -37.21%-2.36 | 69.23%-0.08 | -85.71%-1.04 | 29.09%-0.39 | -145.71%-0.86 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |